InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation
December 12, 2024
Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight against cancer. Calidi’s “recent data on its RTNova(TM) systemic enveloped virotherapy technology demonstrates the potential of cutting-edge solutions to revolutionize cancer care,” the article […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care
December 6, 2024
Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases Platform ‘Designed to Unlock New Possibilities in Cancer Therapy’
December 3, 2024
Calidi Biotherapeutics (NYSE American: CLDI) is focused on discovering more effective treatments amid projections from the American Cancer Society that 2024 will be the first year ever to see two million people diagnosed with cancer. “Calidi Biotherapeutics’ RTNova (‘CLD-400’) is an innovative systemic antitumor enveloped virotherapy designed to unlock new possibilities in cancer therapy. The […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform
November 22, 2024
The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q). Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are working hard to discover more effective treatments […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering
November 19, 2024
Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering, which was conducted under an effective registration statement on Form S-3 […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases RTNova Virotherapy Breakthrough for Metastatic Cancer Treatment
November 18, 2024
Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova™ systemic virotherapy technology. This innovative platform leverages a tumor-selective vaccinia virus enhanced with extracellular enveloped viruses (“EEVs”) to overcome challenges like immune clearance and limited targeting in systemic virotherapy. RTNova […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering to Support Immunotherapy Development
November 14, 2024
Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a public offering with Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. Calidi has priced the offering of 4,437,869 shares at $1.69 per share, aiming to raise approximately $7.5 million in gross proceeds. Calidi […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Is ‘One to Watch’
October 31, 2024
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (“Ovs”) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV Program
October 25, 2024
Calidi Biotherapeutics (NYSE American: CLDI), a leader in oncolytic virotherapy (OV) for cancer, will feature in a RedChip Small Stocks, Big Money™ interview on Bloomberg TV on Oct. 26 at 7 p.m. ET. During the interview, Calidi’s Chief Business Officer, Stephen Thesing, provides an update on Calidi’s innovative approach, which uses engineered viruses to target […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Antitumor Virotherapy Platform Data at Three Scientific Conferences
October 24, 2024
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is set to present data on its innovative systemic antitumor virotherapy platform, RTNova (CLD-400), at multiple scientific conferences. These include the International Oncolytic Virotherapy Conference in Rotterdam (Oct. 27-30), the Immuno US 2024 in San Diego (Oct. 28-29), and the Society for Immunotherapy of Cancer Annual […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member
July 16, 2024
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert […]